CSIMarket Company Name, Ticker, Customers, else..
 
Elutia Inc   (NASDAQ: ELUT)
Other Ticker:  
 
 
Price: $2.9200 $-0.21 -6.709%
Day's High: $3.24 Week Perf: -14.12 %
Day's Low: $ 2.92 30 Day Perf: -31.13 %
Volume (M): 47 52 Wk High: $ 5.24
Volume (M$): $ 136 52 Wk Avg: $3.63
Open: $3.04 52 Wk Low: $2.28



 Market Capitalization (Millions $) 104
 Shares Outstanding (Millions) 36
 Employees -
 Revenues (TTM) (Millions $) 24
 Net Income (TTM) (Millions $) -54
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 1

Elutia Inc
Elutia Inc is a technology company that specializes in developing innovative solutions for the commercial and industrial sectors. The company focuses on creating high-performance computing systems, embedded computing solutions, and advanced data analytics software. Elutia Inc's products and services are designed to improve operational efficiency, enhance productivity, and optimize decision-making processes for its clients. With a strong emphasis on research and development, the company strives to stay at the forefront of technological advancements and provide cutting-edge solutions to its customers.


   Company Address: 12510 Prosperity Drive Silver Spring 20904 MD
   Company Phone Number: 247-1170   Stock Exchange / Ticker: NASDAQ ELUT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP   -4.84%    
ALEC   -13.03%    
DYAI   -8.99%    
NVAX   -11.45%    
VIR   -11.45%    
VXRT   -11.45%    
• View Complete Report
   



Product Service News

Elutia Inc., a leader in the development of advanced medical devices, has recently unveiled a crucial publi...

Published Wed, Sep 18 2024 12:00 PM UTC

Groundbreaking Study Confirms the Efficacy of Elutia s Antibiotic-Eluting BioEnvelope, EluPro, in Preventing Cardiac Device Infections Elutia Inc., a leader in the development of advanced medical devices, has recently unveiled a crucial publication that underscores the formidable effectiveness of its flagship product, the EluPro Antibiotic-Eluting BioEnvelope. This peer-revi...
Product Service News

Elutia Inc. Breaks New Ground with First Implant of FDA-Cleared EluPro BioEnvelope,

Published Thu, Sep 5 2024 8:05 PM UTC

Elutia Inc. Begins a New Era in Cardiac and Neurostimulation Treatment with EluPro BioEnvelope By AbstractElutia Inc. (Nasdaq: ELUT) has announced a significant milestone in the field of cardiac and neurostimulation therapy with the first successful patient implant of EluPro, the world?s first antibiotic-eluting biologic envelope, sanctioned by the U.S. Food and Drug Admin...
Stocks on the Move

The Journey of Elutia Inc Struggles, Successes, and FDA Clearance

Published Fri, Jun 28 2024 10:30 AM UTC

Elutia Inc: Struggles and Successes in the Drug Discovery IndustryThe drug discovery industry is a complex field that requires extensive research, testing, and regulatory approval before a new medication can reach the market. Elutia Inc, a pharmaceutical company specializing in drug-eluting biomatrix products, has recently been in the spotlight due to its various development...
Product Service News

Elutias EluPro FDA Approves Worlds First Antibiotic-Eluting BioEnvelope to Safeguard Cardiac Implant Patients...

Published Mon, Jun 17 2024 12:00 PM UTC

Elutia, a foremost innovator in the field of cardiac medical devices, has marked a historic milestone with the FDA clearance of its latest advancement, EluPro. This pioneering product, touted as the first antibiotic-eluting bioEnvelope, is designed to offer unparalleled protection for patients with implantable cardiac pacemakers and defibrillators. The arrival of EluPro sign...
Financing Agreement

Elutia Inc. Captures Investor Confidence with $13.26 Million Registered Direct Offering for Future Growth

Published Mon, Jun 17 2024 12:01 PM UTC

Elutia Inc. Raises Funds through Registered Direct Offering to Fuel Growth
Silver Spring-based company, Elutia Inc., recently announced a registered direct offering that is set to raise approximately $13.26 million for the company. The offering entails the purchase and sale of 3,175,000 shares of Elutia s Class A common stock, priced at $3.40 per share, along with 725,00...






Elutia Inc's Segments
Device Protection    39.37 % of total Revenue
Women s Health    54 % of total Revenue
Cardiovascular    9.79 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com